The Next Chapter of Renal Denervation After US Food and Drug Administration Approval.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4539 (Electronic) Linking ISSN: 00097322 NLM ISO Abbreviation: Circulation Subsets: MEDLINE
    • Publication Information:
      Publication: Hagerstown, MD : Lippincott Williams & Wilkins
      Original Publication: [Dallas, Tex., etc., American Heart Association, etc.]
    • Subject Terms:
      United States Food and Drug Administration*; United States ; Humans ; Ultrasonography ; Denervation
    • Abstract:
      Competing Interests: Disclosures Dr Addo is Investigator for TARGET BP Trial of Renal Denervation by the Peregrine System (Ablative Solutions). Dr Vongpatanasin reports no conflict.
    • Comments:
      Comment on: Circulation. 2024 Mar 5;149(10):747-759. (PMID: 37883784)
    • Contributed Indexing:
      Keywords: United States Food and Drug Administration; denervation; hypertension; kidney
    • Publication Date:
      Date Created: 20240304 Date Completed: 20240306 Latest Revision: 20240403
    • Publication Date:
      20240404
    • Accession Number:
      10.1161/CIRCULATIONAHA.123.067983
    • Accession Number:
      38437485